Oncopeptides AB (LTS:0RN4) Interest Expense : kr-2.09 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Oncopeptides AB's interest expense for the three months ended in Dec. 2024 was kr 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was kr-2.09 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Oncopeptides AB's Operating Income for the three months ended in Dec. 2024 was kr -83.33 Mil. Oncopeptides AB's Interest Expense for the three months ended in Dec. 2024 was kr 0.00 Mil. GuruFocus does not calculate Oncopeptides AB's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oncopeptides AB Interest Expense Historical Data

The historical data trend for Oncopeptides AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Interest Expense Chart

Oncopeptides AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-1.49

-0.95

-0.88

-5.79

-0.71

Oncopeptides AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-2.09	-	-	-

Oncopeptides AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.09 Mil.

Oncopeptides AB (LTS:0RN4) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oncopeptides AB's Interest Expense for the three months ended in Dec. 2024 was kr0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was kr-83.33 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was kr121.89 Mil.

Oncopeptides AB's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate Oncopeptides AB's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (LTS:0RN4) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB Headlines

No Headlines